Bruker Corporation to Report Q4 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Should l Buy BRKR?
Source: Newsfilter
- Earnings Report Schedule: Bruker Corporation will announce its fourth quarter and fiscal year 2025 financial results before market opening on February 12, 2026, reflecting the company's ongoing development and innovation in the post-genomic era.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Standard Time to discuss the financial results and current business trends, allowing investors to participate via designated phone numbers for efficient information access.
- Webcast Access: Investors can access the “Q4 2025 Earnings Webcast” link in the “Events & Presentations” section of the company’s website, ensuring timely updates on financial information and analysis.
- Replay Service: A telephone replay of the conference call will be available until March 12, allowing investors to listen to the meeting content through specified numbers to further understand the company's financial performance and future outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRKR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRKR
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 41.040
Low
40.00
Averages
52.18
High
60.00
Current: 41.040
Low
40.00
Averages
52.18
High
60.00
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bruker Corporation to Report Q4 2025 Financial Results
- Earnings Report Schedule: Bruker Corporation will announce its fourth quarter and fiscal year 2025 financial results before market opening on February 12, 2026, reflecting the company's ongoing development and innovation in the post-genomic era.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Standard Time to discuss the financial results and current business trends, allowing investors to participate via designated phone numbers for efficient information access.
- Webcast Access: Investors can access the “Q4 2025 Earnings Webcast” link in the “Events & Presentations” section of the company’s website, ensuring timely updates on financial information and analysis.
- Replay Service: A telephone replay of the conference call will be available until March 12, allowing investors to listen to the meeting content through specified numbers to further understand the company's financial performance and future outlook.
See More
Wall Street Trades Cautiously as CPI Rises 2.7% Amid Weak Earnings Reports
- Stable Inflation Data: The Consumer Price Index (CPI) rose 2.7% year-over-year in December, matching both prior readings and economist expectations, indicating that inflationary pressures remain stable and potentially supporting future Federal Reserve rate cuts.
- Silver Price Surge: Supply concerns drove silver prices up 4.5% to $89 per ounce, marking a 22% increase since the start of the year, reflecting strong market demand and heightened risk aversion among investors.
- Major Indices Performance: By midday, the S&P 500 index remained flat at 6,970, close to the record high of 6,986 set the previous day, while the Dow Jones Industrial Average fell 0.5%, indicating cautious market sentiment.
- Stock Movements: Despite JPMorgan Chase (JPM) beating earnings estimates, its stock fell over 3%, reflecting investor concerns over weak investment banking fees, while Moderna (MRNA) surged 14% due to bullish growth forecasts in its vaccine business, highlighting a preference for biotech stocks in the current market environment.
See More
Bruker Corporation Secures $500M Multi-Year Superconductor Agreements with Global Radiology Firms
- Significant Agreement Value: Bruker's BEST division has signed two multi-year supply agreements with global radiology companies, expected to generate approximately $500 million in future revenues, with contract lengths extending up to seven years, highlighting ongoing demand for advanced MRI magnet technologies.
- Technological Support Innovation: Under the new agreements, BEST will supply superconductors engineered to meet stringent MRI magnet performance standards, primarily supporting MRI magnet production in the U.S. and the U.K., leveraging Bruker's manufacturing capabilities across Europe and the U.S. to ensure efficient delivery.
- Sustainability Drive: Bruker's advanced superconductors play a critical role in helium-free MRI magnet architectures, which not only enhance field stability and homogeneity but also reduce operating costs, aligning with the industry's increasing focus on sustainability.
- Increased Market Confidence: Bruker President Burkhard Prause noted that the expanded agreements demonstrate major OEM customers' confidence in their superconductor innovation capabilities and resilient supply chains, ensuring stability and growth in their superconducting business while further solidifying long-term partnerships with clients.
See More
Bruker Corporation Secures $500 Million Superconductor Supply Agreements
- Supply Agreement Expansion: Bruker's Energy & Supercon Technologies division has signed two multi-year supply agreements with global radiology companies, with an expected future revenue of approximately $500 million, further solidifying its leadership in the MRI magnet market.
- Diverse Agreement Durations: One of the agreements extends up to seven years, which not only ensures a long-term revenue stream but also enhances Bruker's competitive position in the superconducting materials sector.
- High-Performance Superconductors: Under the new agreements, Bruker will supply high-performance superconductors to MRI magnet production sites in the U.S. and the U.K., meeting stringent performance and quality requirements, thereby improving customer satisfaction and technological leadership.
- Market-Driven Innovation: Bruker's superconductors support new helium-free MRI magnet architectures, reducing costs and enhancing sustainability, which further drives growth potential in the MRI market.
See More
Grandeur Peak Reduces Bruker Stake by 709,697 Shares, Net Position Change of $29.54 Million
- Stake Reduction: Grandeur Peak Global Advisors sold 709,697 shares of Bruker Corporation in Q3, resulting in a net position change of $29.54 million, indicating a potential decline in confidence for the upcoming years.
- Position Change: As of September 30, Bruker's post-trade holding stands at 34,097 shares valued at approximately $1.11 million, significantly dropping from 3.69% to 0.15% of the fund's AUM, reflecting reduced importance in the portfolio.
- Performance Decline: Bruker reported a 0.5% year-over-year revenue decline in Q3, with organic revenue down 4.5%, highlighting ongoing softness in academic and research spending that could impact future growth expectations.
- Cost-Cutting Initiative: The management plans to implement a $100 million to $120 million cost-down program aimed at boosting margins by 2026, suggesting that while short-term earnings pressures exist, long-term demand drivers remain intact.
See More
Grandeur Peak Reduces Bruker Stake by 709,697 Shares, Valued at $29.54 Million
- Significant Reduction: Grandeur Peak Global Advisors sold 709,697 shares of Bruker in Q3, resulting in a $29.54 million decline in position value, indicating a waning confidence in the company's future performance.
- Position Change: As of September 30, Grandeur Peak's holdings in Bruker dropped to 34,097 shares valued at $1.11 million, moving it out of the fund's top five holdings, which suggests a strategic reallocation of investments.
- Performance Pressure: Bruker's Q3 revenue fell by 0.5% year-over-year, with organic revenue down 4.5%, reflecting ongoing softness in academic and research spending, which could complicate future growth prospects.
- Management's Response Strategy: Bruker's management is betting on a cost-cutting program of $100 million to $120 million aimed at boosting margins, although short-term earnings pressures remain, the long-term demand drivers are still in place.
See More
Bruker Corporation to Report Q4 2025 Financial Results
- Earnings Report Schedule: Bruker Corporation will announce its fourth quarter and fiscal year 2025 financial results before market opening on February 12, 2026, reflecting the company's ongoing development and innovation in the post-genomic era.
- Conference Call Details: The company will host a conference call at 8:30 a.m. Eastern Standard Time to discuss the financial results and current business trends, allowing investors to participate via designated phone numbers for efficient information access.
- Webcast Access: Investors can access the “Q4 2025 Earnings Webcast” link in the “Events & Presentations” section of the company’s website, ensuring timely updates on financial information and analysis.
- Replay Service: A telephone replay of the conference call will be available until March 12, allowing investors to listen to the meeting content through specified numbers to further understand the company's financial performance and future outlook.
See More
Wall Street Trades Cautiously as CPI Rises 2.7% Amid Weak Earnings Reports
- Stable Inflation Data: The Consumer Price Index (CPI) rose 2.7% year-over-year in December, matching both prior readings and economist expectations, indicating that inflationary pressures remain stable and potentially supporting future Federal Reserve rate cuts.
- Silver Price Surge: Supply concerns drove silver prices up 4.5% to $89 per ounce, marking a 22% increase since the start of the year, reflecting strong market demand and heightened risk aversion among investors.
- Major Indices Performance: By midday, the S&P 500 index remained flat at 6,970, close to the record high of 6,986 set the previous day, while the Dow Jones Industrial Average fell 0.5%, indicating cautious market sentiment.
- Stock Movements: Despite JPMorgan Chase (JPM) beating earnings estimates, its stock fell over 3%, reflecting investor concerns over weak investment banking fees, while Moderna (MRNA) surged 14% due to bullish growth forecasts in its vaccine business, highlighting a preference for biotech stocks in the current market environment.
See More
Bruker Corporation Secures $500M Multi-Year Superconductor Agreements with Global Radiology Firms
- Significant Agreement Value: Bruker's BEST division has signed two multi-year supply agreements with global radiology companies, expected to generate approximately $500 million in future revenues, with contract lengths extending up to seven years, highlighting ongoing demand for advanced MRI magnet technologies.
- Technological Support Innovation: Under the new agreements, BEST will supply superconductors engineered to meet stringent MRI magnet performance standards, primarily supporting MRI magnet production in the U.S. and the U.K., leveraging Bruker's manufacturing capabilities across Europe and the U.S. to ensure efficient delivery.
- Sustainability Drive: Bruker's advanced superconductors play a critical role in helium-free MRI magnet architectures, which not only enhance field stability and homogeneity but also reduce operating costs, aligning with the industry's increasing focus on sustainability.
- Increased Market Confidence: Bruker President Burkhard Prause noted that the expanded agreements demonstrate major OEM customers' confidence in their superconductor innovation capabilities and resilient supply chains, ensuring stability and growth in their superconducting business while further solidifying long-term partnerships with clients.
See More
Bruker Corporation Secures $500 Million Superconductor Supply Agreements
- Supply Agreement Expansion: Bruker's Energy & Supercon Technologies division has signed two multi-year supply agreements with global radiology companies, with an expected future revenue of approximately $500 million, further solidifying its leadership in the MRI magnet market.
- Diverse Agreement Durations: One of the agreements extends up to seven years, which not only ensures a long-term revenue stream but also enhances Bruker's competitive position in the superconducting materials sector.
- High-Performance Superconductors: Under the new agreements, Bruker will supply high-performance superconductors to MRI magnet production sites in the U.S. and the U.K., meeting stringent performance and quality requirements, thereby improving customer satisfaction and technological leadership.
- Market-Driven Innovation: Bruker's superconductors support new helium-free MRI magnet architectures, reducing costs and enhancing sustainability, which further drives growth potential in the MRI market.
See More
Grandeur Peak Reduces Bruker Stake by 709,697 Shares, Net Position Change of $29.54 Million
- Stake Reduction: Grandeur Peak Global Advisors sold 709,697 shares of Bruker Corporation in Q3, resulting in a net position change of $29.54 million, indicating a potential decline in confidence for the upcoming years.
- Position Change: As of September 30, Bruker's post-trade holding stands at 34,097 shares valued at approximately $1.11 million, significantly dropping from 3.69% to 0.15% of the fund's AUM, reflecting reduced importance in the portfolio.
- Performance Decline: Bruker reported a 0.5% year-over-year revenue decline in Q3, with organic revenue down 4.5%, highlighting ongoing softness in academic and research spending that could impact future growth expectations.
- Cost-Cutting Initiative: The management plans to implement a $100 million to $120 million cost-down program aimed at boosting margins by 2026, suggesting that while short-term earnings pressures exist, long-term demand drivers remain intact.
See More
Grandeur Peak Reduces Bruker Stake by 709,697 Shares, Valued at $29.54 Million
- Significant Reduction: Grandeur Peak Global Advisors sold 709,697 shares of Bruker in Q3, resulting in a $29.54 million decline in position value, indicating a waning confidence in the company's future performance.
- Position Change: As of September 30, Grandeur Peak's holdings in Bruker dropped to 34,097 shares valued at $1.11 million, moving it out of the fund's top five holdings, which suggests a strategic reallocation of investments.
- Performance Pressure: Bruker's Q3 revenue fell by 0.5% year-over-year, with organic revenue down 4.5%, reflecting ongoing softness in academic and research spending, which could complicate future growth prospects.
- Management's Response Strategy: Bruker's management is betting on a cost-cutting program of $100 million to $120 million aimed at boosting margins, although short-term earnings pressures remain, the long-term demand drivers are still in place.
See More
